Target
RAF-1
12 abstracts
Abstract
First-line regorafenib with nivolumab and FOLFOX or CapeOX in patients with advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: A single-arm, phase Ib/II trial (REGONIVOCTx, EPOC2104).Org: National Cancer Center Hospital East, Kashiwa, Japan, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Chiba, Japan,
Abstract
CVM-1118: A potent oral anti-vasculogenic mimicry (VM) agent in combination with nivolumab in patients with unresectable advanced hepatocellular carcinoma (HCC)—A phase IIa study.Org: Department of Surgery, National Cheng Kung University Hospital, Tainan, Taiwan, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, Division of Hepato-Gastroenterology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan,
Abstract
Efficacy and safety of regorafenib plus ICIs as second-line treatment in advanced HCC post-frontline treatment failure: A real-world study from a single center.Org: PLA General Hospital,
Abstract
Overall survival (OS) of phase 3 CodeBreaK 300 study of sotorasib plus panitumumab (soto+pani) versus investigator’s choice of therapy for KRAS G12C-mutated metastatic colorectal cancer (mCRC).Org: Global Biostatistical Science, Global Development,
Abstract
Regorafenib in older adults with metastatic colorectal cancer: A multi-center, single arm phase II trial.Org: Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, Fox Chase Cancer Center, Temple University Health System,
Abstract
Regorafenib second-line therapy for surgical recurrent hepatocellular carcinoma: An exploration of continuing regorafenib therapy after tumor progression—A single-center retrospective analysis of 90 cases.Org: Liver Disease Center, The Affiliated Hospital of Qingdao University, Qingdao, China, Department of Interventional medicine,The Affiliated Hospital of Qingdao University, Qingdao, China, Organ Transplantation Center,
Abstract
Efficacy and safety of regorafenib + PD-1 inhibitor combined with local therapy as second-line treatment in patients with advanced hepatocellular carcinoma: A multicenter retrospective real-world study.Org: Sun Yat-sen University Cancer Center, Guangzhou, China,
Abstract
Examining the treatment journey of patients diagnosed with hepatocellular carcinoma (HCC) using retrospective real-world data in British Columbia, Canada.Org: Sunnybrook Research Institute, BMZ Analytics, BC Cancer Agency Vancouver Island Centre, University of British Columbia, British Columbia Cancer Agency,
Abstract
The efficacy and safety of toripalimab combined with sorafenib for unresectable hepatocellular carcinoma: An open-label, prospective, single-arm phase II study.Org: Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University; Key Laboratory of Carcinogenesis and Cancer Invasion (Fudan University), Ministry of Education, Shanghai, China, Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China, Zhongshan Hospital of Fudan University, Shanghai, China, Fudan University (Xiamen Branch), Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Fudan University,
Abstract
Analysis of the efficacy and safety of PD-1/PD-L1 inhibitors–based treatment in myxofibrosarcoma: A single-institution retrospective analysis.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Zhongshan Hospital of Fudan University, Shanghai, China, Fudan University (Xiamen Branch), Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
A real-world study of TACE combined with regorafenib as a second-line treatment for advanced hepatocellular carcinoma.Org: Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing),
Abstract
Regorafenib as a first-line agent alone or in combination with an immune checkpoint inhibitor for advanced hepatocellular carcinoma efficacy and safety of patients: A real-world study.Org: Department of Hepatobiliary Surgery, Tianjin First Central Hospital, Tianjin, China, Department of Hepatobiliary and Pancreatic Surgery, Tianjin First Central Hospital，Nankai University, Tianjin, China, Nankai University, Tianjin, China, Tianjin medical University, Tianjin, China,